Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen

June 09, 2021 By The ASCO Post Staff

Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab (Abstract 503).

Related Content